Arcturus Therapeutics Holdings's quarterly market cap
declined
from Sep. 2025 ($501.94 Mil) to Dec. 2025 ($174.18 Mil) but then
increased
from Dec. 2025 ($174.18 Mil) to Mar. 2026 ($219.43 Mil).
Arcturus Therapeutics Holdings's annual market cap
declined
from Dec. 2023 ($845.89 Mil) to Dec. 2024 ($458.19 Mil) and
declined
from Dec. 2024 ($458.19 Mil) to Dec. 2025 ($174.18 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Arcturus Therapeutics Holdings's Enterprise Value for Today is $6.46 Mil.
Arcturus Therapeutics Holdings (NAS:ARCT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Arcturus Therapeutics Holdings Market Cap Related Terms
Arcturus Therapeutics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Market Cap falls into.
Arcturus Therapeutics Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a Market Cap of $193.70 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arcturus Therapeutics Holdings and its competitors. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #602 out of 1431 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Arcturus Therapeutics Holdings' Market Cap too high?
Arcturus Therapeutics Holdings' current Market Cap is $193.70 Mil. The Biotechnology industry median Market Cap is 117.63. Arcturus Therapeutics Holdings' value of $193.70 Mil is 64.7% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #602 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Market Cap compare to YDES and RNAC?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #602 out of 1431 companies for Market Cap. This puts Arcturus Therapeutics Holdings in the upper half of its industry. The industry median Market Cap is 117.63. Arcturus Therapeutics Holdings' value of $193.70 Mil is 64.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Market Cap of $193.70 Mil is 64.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Market Cap is $193.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.5% above its estimated fair value. The current Market Cap is $193.70 Mil and 64.7% above the Biotechnology industry median of 117.63. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Market Cap is $193.70 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $6.82 is trading 54.5% above its estimated GF Value™ of $4.41.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
Market Cap: $193.70 Mil
GF Value™: $4.41 vs. price of $6.82 (54.5% above fair value)
Industry Position: 64.7% above the Biotechnology median (#602 of 1431)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score
Get the complete analysis for ARCT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
